An advisory panel of the US Food and Drug Administration has recommended approval of Novartis’s indacaterol as the first once-daily, long-term maintenance bronchodilator treatment for patients with chronic obstructive pulmonary disease.
Topotarget A/S of Denmark reported revenue of DKK 129 million (€17.3 million) in 2010, up from DKK 44 million a year earlier, boosted by an upfront payment from its co-development partner for its lead cancer drug, belinostat.
UCB SA of Belgium has completed the placement of €300 million in perpetual subordinated bonds as part of an ongoing effort to restructure its balance sheet. The new bonds will qualify as equity, the company said.
The US Patent and Trademark Office has awarded a patent to the privately-owned Symphogen A/S of Denmark for an oncology compound that is based on a mixture of two anti-epidermal growth factor receptor (EGFR) monoclonal antibodies.
AstraZeneca Plc and Bristol-Myers Squibb Co have won a label update in Europe and the US for their Type 2 diabetes drug, Onglyza (saxagliptin), for adults with Type 2 diabetes who have moderate or severe renal impairment.
An investigational drug for patients with Type 2 diabetes has failed to show non-inferiority in a clinical trial that compared it with a competitor. The drug, Bydureon, is an extended release formulation of exenatide.
Galápagos NV, the Belgian drug discovery and development company, achieved a net profit of €4.4 million in 2010 compared with €3 million the previous year while increasing its spending on research and development by 41% to €84.7 million.
The Renovo Group Plc is reducing its staff and the size of its board of directors in the wake of the failure of a Phase 3 trial of its wound-healing product, Juvista. Recruitment is also being stopped for a trial of a second tissue product.
A group of Danish researchers, backed by a DKK 90 million (€12 mln) grant from the Danish National Advanced Technology Foundation, have joined forces to identify still-unknown pathogens that may cause cancer. Bavarian Nordic is a project partner.
UCB SA of Belgium is to allocate up to $6 million over two years to a new collaboration with Harvard University focusing on research into future therapeutics for immunological diseases and diseases of the central nervous system.